Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and mFLOT in Metastatic Gastric Cancer
NCT05982301Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in gastric cancer (GC), sponsored by Fudan University. Started Feb 2023; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05982301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05982301.